1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H1 2020, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.
Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 14, 76, 93, 1, 4, 93, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 8, 4, 1, 12 and 3 molecules, respectively.
Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Bladder Cancer - Overview
- Bladder Cancer - Therapeutics Development
- Bladder Cancer - Therapeutics Assessment
- Bladder Cancer - Companies Involved in Therapeutics Development
- Bladder Cancer - Drug Profiles
- Bladder Cancer - Dormant Projects
- Bladder Cancer - Discontinued Products
- Bladder Cancer - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Bladder Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Bladder Cancer - Pipeline by 4D Pharma Plc, H1 2020
- Bladder Cancer - Pipeline by 4SC AG, H1 2020
- Bladder Cancer - Pipeline by Aadi Bioscience Inc, H1 2020
- Bladder Cancer - Pipeline by AbbVie Inc, H1 2020
- Bladder Cancer - Pipeline by Abivax SA, H1 2020
- Bladder Cancer - Pipeline by Actuate Therapeutics Inc, H1 2020
- Bladder Cancer - Pipeline by ADC Therapeutics SA, H1 2020
- Bladder Cancer - Pipeline by Aduro BioTech Inc, H1 2020
- Bladder Cancer - Pipeline by Advaxis Inc, H1 2020
- Bladder Cancer - Pipeline by Agenus Inc, H1 2020
- Bladder Cancer - Dormant Projects, H1 2020
- Bladder Cancer - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Bladder Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Pharma Plc
- 4SC AG
- Aadi Bioscience Inc
- AbbVie Inc
- Abivax SA
- Actuate Therapeutics Inc
- ADC Therapeutics SA
- Aduro BioTech Inc
- Advaxis Inc
- Agenus Inc
- AIM ImmunoTech Inc
- Alligator Bioscience AB
- Alphamab Oncology
- Altor Bioscience LLC
- Amrita Therapeutics
- Andes Biotechnologies
- Angex Pharmaceutical Inc
- Apexian Pharmaceuticals Inc
- APIM Therapeutics AS
- Apollomics Inc
- Aprea Therapeutics AB
- Aravive Inc
- Archivel Farma SL
- Arcus Biosciences Inc
- Arisaph Pharmaceuticals Inc
- Asieris Pharmaceuticals Co Ltd
- AstraZeneca Plc
- Aura Biosciences Inc
- Aurigene Discovery Technologies Ltd
- Aurora Oncology Inc
- Bavarian Nordic A/S
- Bayer AG
- BeiGene Ltd
- Beijing Neoantigen Biotechnology Co Ltd
- BerGenBio ASA
- Betta Pharmaceuticals Co Ltd
- BeyondSpring Inc
- Bio-Thera Solutions Ltd
- BioAtla LLC
- Biocad
- Biohaven Pharmaceutical Holding Company Ltd
- BioMed Valley Discoveries Inc
- Biomics Biotechnologies Co Ltd
- BioNTech SE
- Biosion Inc
- Black Diamond Therapeutics Inc
- Bliss Biopharmaceutical (Hangzhou) Co Ltd
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Cantargia AB
- CDR-Life Inc
- CellCentric Ltd
- Celldex Therapeutics Inc
- Celon Pharma SA
- Celprogen Inc
- Celsion Corp
- Celyad Oncology
- CG Oncology Inc
- Checkmate Pharmaceuticals Inc
- CheckPoint Immunology Inc
- CicloMed LLC
- Cleveland BioLabs Inc
- CMG Pharmaceutical Co Ltd
- Constellation Pharmaceuticals Inc
- Convalife
- Corvus Pharmaceuticals Inc
- CStone Pharmaceuticals Co Ltd
- Cytodyn Inc
- CytomX Therapeutics Inc
- Daiichi Sankyo Co Ltd
- DelMar Pharmaceuticals Inc
- Ectin Research AB
- Eddingpharm Inc
- Eisai Co Ltd
- Emtora Biosciences
- ENB Therapeutics LLC
- enGene Inc
- EnGeneIC Ltd
- EpiVax Oncology Inc
- Esperance Pharmaceuticals Inc
- Evelo Biosciences Inc
- Exelixis Inc
- Exicure Inc
- EXUMA Biotech Inc
- F. Hoffmann-La Roche Ltd
- Fidia farmaceutici SpA
- FKD Therapies Oy
- For-Robin Inc
- Fusion Pharmaceuticals Inc
- Gene Signal International SA
- Genentech Inc
- Genexine Inc
- Genmab AS
- Genome & Co
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- GLG Pharma SA
- GlycoNex Inc
- H3 Biomedicine Inc
- Hamlet Pharma AB
- Hanmi Pharmaceuticals Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- HengRui YuanZheng Bio-Technology Co Ltd
- Hope Biosciences Inc
- Horizon Therapeutics Plc
- Huabo Biopharm Co Ltd
- I-Mab Biopharma Co Ltd
- ImCheck Therapeutics SAS
- ImmunityBio Inc
- Immunocore Ltd
- Immunomic Therapeutics Inc
- ImmunSYS Inc
- Immupharma Plc
- Imugene Ltd
- IMV Inc
- Incanthera Ltd
- Incyte Corp
- Innovative Cellular Therapeutics Co Ltd
- Innovent Biologics Inc
- Invectys SA
- Iovance Biotherapeutics Inc
- Jacobio Pharmaceuticals Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- KLUS Pharma Inc
- Komipharm International Co Ltd
- Kyowa Kirin Co Ltd
- Lipac Oncology LLC
- LipoMedix Pharmaceutical Inc
- LipoSeuticals Inc
- Loxo Oncology Inc
- Luye Pharma Group Ltd
- Lycera Corp
- Machavert Pharmaceuticals LLC
- MacroGenics Inc
- Manhattan Biosolutions LLC
- MaxiVAX SA
- Mediolanum farmaceutici SpA
- Medivir AB
- MedPacto Inc
- MELEMA Pharma GmbH
- Merck & Co Inc
- Merck KGaA
- Midissia Therapeutics Inc
- Millennium Pharmaceuticals Inc
- Modra Pharmaceuticals BV
- Molecular Partners AG
- Molecular Templates Inc
- Moleculin Biotech LLC
- Morvus Technology Ltd
- MTG Biotherapeutics Inc
- Mustang Bio Inc
- Nanjing Transthera Biosciences Co Ltd
- NanoCarrier Co Ltd
- Nanology LLC
- NantKwest Inc
- Nektar Therapeutics
- NeoTX Therapeutics Ltd
- NGM Biopharmaceuticals Inc
- Northwest Biotherapeutics Inc
- Novartis AG
- Ocellaris Pharma Inc
- Ona Therapeutics SL
- OncoSTING LLC
- OncoTherapy Science Inc
- Oncovir Inc
- Ono Pharmaceutical Co Ltd
- Optimum Therapeutics LLC
- Oxford BioTherapeutics Ltd
- Peptron Inc
- Pfizer Inc
- Pharma Mar SA
- Pieris Pharmaceuticals Inc
- Plus Therapeutics Inc
- Prokarium Ltd
- Provecs Medical GmbH
- PsiOxus Therapeutics Ltd
- Puma Biotechnology Inc
- Qu Biologics Inc
- Quadriga BioSciences Inc
- Ractigen Therapeutics Inc
- Rainier Therapeutics Inc
- RemeGen Ltd
- Replimune Ltd
- Rexahn Pharmaceuticals Inc
- Sanofi
- Sareum Holdings Plc
- Savoy Pharmaceuticals Inc
- Scholar Rock Inc
- Scopus BioPharma Inc
- Seattle Genetics Inc
- Serum Institute of India Ltd
- Sesen Bio Inc
- SetLance srl
- Seven and Eight Biopharmaceuticals Corp
- Shionogi & Co Ltd
- Sillajen Biotherapeutics
- Sitka Biopharma Inc
- Sotio AS
- Spectrum Pharmaceuticals Inc
- Spring Bank Pharmaceuticals Inc
- Stcube Inc
- Syndax Pharmaceuticals Inc
- T-Cure Bioscience Inc
- Targovax ASA
- Tarus Therapeutics Inc
- Tempest Therapeutics Inc
- Tessa Therapeutics Pte Ltd
- Theralase Technologies Inc
- Tmunity Therapeutics Inc
- Tolero Pharmaceuticals Inc
- Tollys SAS
- Toray Industries Inc
- Transgene SA
- Treos Bio Ltd
- UbiVac LLC
- UroGen Pharma Ltd
- VasGene Therapeutics Inc
- Vault Pharma Inc
- Vaxiion Therapeutics Inc
- Viralytics Pty Ltd
- Vivlmmune Inc
- Vyriad Inc
- Xbrane Biopharma AB
- Xiangxue Life Sciences
- Zhejiang Teruisi Pharmaceutical Inc
- Zhejiang Yangshengtang Biotech Co Ltd
- Zymeworks Inc
